Skip to main content
SpringerLink
Log in

Pharmacology of Male Sexual Function

  • Chapter
  • First Online:
Urologic Principles and Practice

Part of the book series: Springer Specialist Surgery Series ((SPECIALIST))

  • 1200 Accesses

Abstract

Male sexual dysfunction represents a relevant problem that can significantly affect the overall quality of life of men. This term encompasses a variety of clinical conditions such as, but not limiting to, erectile dysfunction, premature ejaculation and penile curvatures.

The treatment of these conditions comprises different lines of either pharmacological or surgical therapy. The aim of this chapter is to describe the pharmacological approach to the treatment of these conditions according to the latest scientific evidences.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. NIH Consensus Conference. Impotence NIH Consensus Development Panel on Impotence. 1993. p. 83–90.

    Google Scholar 

  2. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014;11(6):1423–41.

    Article  PubMed  Google Scholar 

  3. Tanagho EA, McAninch JW. Smith’s General Urology 17th edition, McGraw-Hill Professional. 2007

    Google Scholar 

  4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61.

    Article  CAS  PubMed  Google Scholar 

  5. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res. 2000;12(6):305–11.

    Article  CAS  PubMed  Google Scholar 

  6. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. 2016. p. 144–52.

    Google Scholar 

  7. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M, et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004;20(5):607–17.

    Article  PubMed  Google Scholar 

  8. Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man—worrisome picture from the everyday clinical practice. J Sex Med. 2013;10(7):1833–41.

    Article  PubMed  Google Scholar 

  9. Capogrosso P, Ventimiglia E, Boeri L, Cazzaniga W, Chierigo F, Pederzoli F, et al. Age at first presentation for erectile dysfunction: analysis of changes over a 12-yr period. Eur Urol Focus. 2018;0(0):1–7.

    Google Scholar 

  10. Moreland RB, Hsieh G, Nakane M, Brioni JD. The biochemical and neurologic basis for the treatment of male erectile dysfunction. J Pharmacol Exp Ther. 2001;296(2):225–34.

    CAS  PubMed  Google Scholar 

  11. Traish AM, Carson MP, Kim N, Goldstein I, Saenz de Tejada I. Characterization of muscarinic acetylcholine receptors in human penile corpus cavernosum: studies on whole tissue and cultured endothelium. J Urol. 1990;144(4):1036–40.

    Article  CAS  PubMed  Google Scholar 

  12. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417–50.

    CAS  PubMed  Google Scholar 

  13. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. 1993;45(3):253–308.

    CAS  PubMed  Google Scholar 

  14. Andersson KE, Stief C. Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. World J Urol. 2001;19(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  15. Steers WD. Pharmacologic treatment of erectile dysfunction. Rev Urol. 2002;4(Suppl 3):S17–25.

    PubMed  PubMed Central  Google Scholar 

  16. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. Guideline Associates: Parnham A, Serefoglu E.C. EAU–Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism. https://uroweb.org/guideline/male-sexual-dysfunction/. Access date [23/04/2019].

  17. Jackson G, Montorsi P, Adams MA, Anis T, El-Sakka A, Miner M, et al. Cardiovascular aspects of sexual medicine. J Sex Med. 2010;7(4):1608–26.

    Article  PubMed  Google Scholar 

  18. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, et al. Endocrine aspects of male sexual dysfunctions. 2010. p. 1627–56.

    Google Scholar 

  19. Eisenberg ML, Kim S, Chen Z, Sundaram R, Schisterman EF, Buck Louis GM. The relationship between male BMI and waist circumference on semen quality: data from the LIFE study. Hum Reprod. 2014;29(2):193–200.

    Article  PubMed  Google Scholar 

  20. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978–84.

    Article  CAS  PubMed  Google Scholar 

  21. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171(20):1797–803.

    Article  PubMed  Google Scholar 

  22. Caskurlu T, Tasci AI, Resim S, Sahinkanat T, Ergenekon E. The etiology of erectile dysfunction and contributing factors in different age groups in Turkey. Int J Urol. 2004;11(7):525–9.

    Article  PubMed  Google Scholar 

  23. Hatzimouratidis K, Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2016;13(4):465–88.

    Article  PubMed  Google Scholar 

  24. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96(3):257–80.

    Article  CAS  PubMed  Google Scholar 

  25. Lue TF. Erectile dysfunction. In: Wood AJJ, editor. N Engl J Med. 2000;342(24):1802–13.

    Google Scholar 

  26. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Part 1):1332–6.

    Article  CAS  PubMed  Google Scholar 

  27. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–5; discussion 125–6

    Article  PubMed  Google Scholar 

  28. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–404. https://doi.org/10.1056/NEJM199805143382001.

    Article  CAS  PubMed  Google Scholar 

  29. Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902–12.

    Article  CAS  PubMed  Google Scholar 

  30. Goldstein I, Tseng L-J, Creanga D, Stecher V, Kaminetsky JC. Efficacy and safety of sildenafil by age in men with erectile dysfunction. J Sex Med. 2016;13(5):852–9.

    Article  PubMed  Google Scholar 

  31. Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract. 2002;56(4):300–4.

    CAS  PubMed  Google Scholar 

  32. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180(4):1228–34.

    Article  CAS  PubMed  Google Scholar 

  33. Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667–73.

    Article  PubMed  Google Scholar 

  34. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med. 2013;10(8):2044–52.

    Article  PubMed  Google Scholar 

  35. Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol. 2005;47(5):612–21.

    Article  CAS  PubMed  Google Scholar 

  36. Chung E, Broc GB. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011;12(8):1341–8.

    Article  CAS  PubMed  Google Scholar 

  37. Sanford M. Vardenafil orodispersible tablet. Drugs. 2012;72(1):87–98.

    Article  CAS  PubMed  Google Scholar 

  38. Debruyne FMJ, Gittelman M, Sperling H, Börner M, Beneke M. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med. 2011;8(10):2912–23.

    Article  CAS  PubMed  Google Scholar 

  39. Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, et al. Avanafil—a further step to tailoring patient needs and expectations. Expert Rev Clin Pharmacol. 2016;9(9):1171–81.

    Article  CAS  PubMed  Google Scholar 

  40. Goldstein I, McCullough AR, Jones LA, Hellstrom WJ, Bowden CH, DiDonato K, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9(4):1122–33.

    Article  CAS  PubMed  Google Scholar 

  41. Wang R, Burnett AL, Heller WH, Omori K, Kotera J, Kikkawa K, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012;9(8):2122–9.

    Article  CAS  PubMed  Google Scholar 

  42. Chen L, Staubli SEL, Schneider MP, Kessels AG, Ivic S, Bachmann LM, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674–80.

    Article  CAS  PubMed  Google Scholar 

  43. Corona G, Rastrelli G, Burri A, Serra E, Gianfrilli D, Mannucci E, et al. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. Andrology. 2016;4(6):1002–9.

    Article  CAS  PubMed  Google Scholar 

  44. Ventimiglia E, Capogrosso P, Montorsi F, Salonia A. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf. 2016;15(2):141–52.

    Article  CAS  PubMed  Google Scholar 

  45. Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine. 2004;23(2–3):149–55.

    Article  CAS  PubMed  Google Scholar 

  46. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7(1):524–40.

    Article  CAS  PubMed  Google Scholar 

  47. Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–71.

    Article  CAS  PubMed  Google Scholar 

  48. Adaikan PG, Karim SM, Kottegoda SR, Ratnam SS. Cholinoreceptors in the corpus cavernosum muscle of the human penis. J Auton Pharmacol. 1983;3(2):107–11.

    Article  CAS  PubMed  Google Scholar 

  49. Sogari PR, Telöken C, Souto CA. Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 1997;158(5):1760–3.

    Article  CAS  PubMed  Google Scholar 

  50. Gupta R, Kirschen J, Barrow RC, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol. 1997;157(5):1681–6.

    Article  CAS  PubMed  Google Scholar 

  51. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 2009;334(14):873–7. https://doi.org/10.1056/NEJM199604043341401.

    Article  Google Scholar 

  52. Yuan J, Hoang AN, Romero CA, Lin H, Dai Y, Wang R. Vacuum therapy in erectile dysfunction—science and clinical evidence. Int J Impot Res. 2010;22(4):211–9.

    Article  CAS  PubMed  Google Scholar 

  53. Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68(2):386–91.

    Article  PubMed  Google Scholar 

  54. Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, Steidle C. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009;6(2):520–34.

    Article  CAS  PubMed  Google Scholar 

  55. Cai T, Palumbo F, Liguori G, Mondaini N, Scroppo FI, Di Trapani D, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019;31(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  56. James Anaissie WJH. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. Res Rep Urol. 2016;8:123–31.

    PubMed  PubMed Central  Google Scholar 

  57. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study roup. N Engl J Med. 1997;336(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  58. Giuliano F, Clément P. Physiology of ejaculation: emphasis on serotonergic control. Eur Urol. 2005;48(3):408–17.

    Article  PubMed  Google Scholar 

  59. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005;2(3):358–67.

    Article  PubMed  Google Scholar 

  60. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17(1):39–57.

    Article  CAS  PubMed  Google Scholar 

  61. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. J Sex Med. 2011;8(2):540–8.

    Article  PubMed  Google Scholar 

  62. Gao J, Zhang X, Su P, Liu J, Xia L, Yang J, et al. Prevalence and factors associated with the complaint of premature ejaculation and the four premature ejaculation syndromes: a large observational study in China. J Sex Med. 2013;10(7):1874–81.

    Article  PubMed  Google Scholar 

  63. McMahon CG, Lee G, Park JK, Adaikan PG. Premature ejaculation and erectile dysfunction prevalence and attitudes in the Asia-Pacific region. J Sex Med. 2012;9(2):454–65.

    Article  CAS  PubMed  Google Scholar 

  64. Gao J, Zhang X, Su P, Shi K, Tang D, Hao Z, et al. Prevalence and impact of premature ejaculation in outpatients complaining of ejaculating prematurely: using the instruments of intravaginal ejaculatory latency time and patient-reported outcome measures. Int J Impot Res. 2014;26(3):94–9.

    Article  CAS  PubMed  Google Scholar 

  65. Jannini EA, Simonelli C, Lenzi A. Sexological approach to ejaculatory dysfunction. Int J Androl. 2002;25(6):317–23.

    Article  CAS  PubMed  Google Scholar 

  66. Melnik T, Althof S, Atallah ÁN, Santos Puga dos ME, Glina S, Riera R. Psychosocial interventions for premature ejaculation. In: Cochrane Urology Group, editor. Cochrane Database Syst Rev. 2011;13(8):41.

    Google Scholar 

  67. Richardson D, Goldmeier D, Green J, Lamba H, Harris JRW, BASHH Special Interest Group for Sexual Dysfunction. Recommendations for the management of premature ejaculation: BASHH Special Interest Group for Sexual Dysfunction. Int J STD AIDS. 2006;17:1–6.

    Article  PubMed  Google Scholar 

  68. McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2004;1(1):58–65.

    Article  PubMed  Google Scholar 

  69. Pastore AL, Palleschi G, Leto A, Pacini L, Iori F, Leonardo C, et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int J Androl. 2012;35(4):528–33.

    Article  CAS  PubMed  Google Scholar 

  70. Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol. 2007;177(3):1065–70.

    Article  PubMed  Google Scholar 

  71. Grenier G, Byers ES. Rapid ejaculation: a review of conceptual, etiological, and treatment issues. Arch Sex Behav. 1995;24(4):447–72.

    Article  CAS  PubMed  Google Scholar 

  72. Metz ME, Pryor JL, Nesvacil LJ, Abuzzahab F, Koznar J. Premature ejaculation: a psychophysiological review. J Sex Marital Ther. 1997;23(1):3–23.

    Article  CAS  PubMed  Google Scholar 

  73. De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav. 1985;14(6):467–89.

    Article  PubMed  Google Scholar 

  74. Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, et al. Behavioral therapies for management of premature ejaculation: a systematic review. Sex Med. 2015;3(3):174–88.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol. 2006;46(3):301–9.

    Article  CAS  PubMed  Google Scholar 

  76. eMC. Priligy 30 mg and 60 mg film-coate tablets. Summary of Product Characteristics [Internet]. https://www.medecines.org.uk/emc/medicine/28284/SPC/Priligy+30+mg+and+60+mg+film-coated+tablets/

  77. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8(2):524–39.

    Article  PubMed  Google Scholar 

  78. Giuliano F. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci. 2007;30(2):79–84.

    Article  CAS  PubMed  Google Scholar 

  79. Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol. 1998;13(Suppl 6):S9–14.

    Article  PubMed  Google Scholar 

  80. Castiglione F, Albersen M, Hedlund P, Gratzke C, Salonia A, Giuliano F. Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. Eur Urol. 2016;69(5):904–16.

    Article  CAS  PubMed  Google Scholar 

  81. Waldinger MD, Zwinderman AH, Olivier B. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001;21(6):556–60.

    Article  CAS  PubMed  Google Scholar 

  82. Waldinger MD. Premature ejaculation: state of the art. Urol Clin North Am. 2007;34(4). 591–9, vii–viii.

    Google Scholar 

  83. McMahon CG, Porst H. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. J Sex Med. 2011;8(10):2707–25.

    Article  CAS  PubMed  Google Scholar 

  84. Farnia V, Raisi F, Mohseni MG, Atharikia D, Ghafuri Z. On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Med Iranica. 2009;47(5):353–7.

    CAS  Google Scholar 

  85. Gameel T, Tawfeek A, Farha MA, Bastawesy M, Bendary M, Gamasy A. 184 on-demand use of Tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. J Sex Med. 2018;15(2):S57.

    Article  Google Scholar 

  86. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol. 1999;161(6):1826–30.

    Article  CAS  PubMed  Google Scholar 

  87. Xia J-D, Han Y-F, Zhou L-H, Chen Y, Dai Y-T. Efficacy and safety of local anaesthetics for premature ejaculation: a systematic review and meta-analysis. Asian J Androl. 2013;15(4):497–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Pu C, Yang L, Liu L, Yuan H, Wei Q, Han P. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology. 2013;81(4):799–804.

    Article  PubMed  Google Scholar 

  89. Waldinger MD. Drug treatment options for premature ejaculation. Expert Opin Pharmacother. 2018;19(10):1077–85.

    Article  CAS  PubMed  Google Scholar 

  90. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103(7):940–9.

    Article  CAS  PubMed  Google Scholar 

  91. Bar-Or D, Salottolo KM, Orlando A, Winkler JV, Tramadol ODT Study Group. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol. 2012;61(4):736–43.

    Article  CAS  PubMed  Google Scholar 

  92. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. Eur Urol. 2012;62:543–52.

    Article  PubMed  Google Scholar 

  93. LaRochelle JC, Levine LAA. Survey of primary-care physicians and urologists regarding Peyronie’s disease. J Sex Med. 2007;4(4 Pt 2):1167–73.

    Article  PubMed  Google Scholar 

  94. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016;13(6):905–23.

    Article  PubMed  Google Scholar 

  95. Abdel Raheem A, Johnson M, Abdel-Raheem T, Capece M, Ralph D. Collagenase clostridium histolyticum in the treatment of Peyronie’s disease-a review of the literature and a new modified protocol. Sex Med Rev. 2017;5(4):529–35.

    Article  PubMed  Google Scholar 

  96. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des. 2005;11(31):4041–6.

    Article  CAS  PubMed  Google Scholar 

  97. Gonzalez-Cadavid N, Ignarro L, Rajfer J. Nitric oxide and the cyclic GMP system in the penis. Mol Urol. 1999;3(2):51–9.

    CAS  PubMed  Google Scholar 

  98. Sinnaeve P, Chiche J-D, Gillijns H, Van Pelt N, Wirthlin D, Van De Werf F, et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation. 2002;105(24):2911–6.

    Article  CAS  PubMed  Google Scholar 

  99. Iacono F, Prezioso D, Somma P, Chierchia S, Galasso R, Micheli P. Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol Int. 2008;80(3):249–52.

    Article  CAS  PubMed  Google Scholar 

  100. Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie’s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7(4):215–21.

    Article  CAS  PubMed  Google Scholar 

  101. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472–7.

    Article  CAS  PubMed  Google Scholar 

  102. Brant WO, Dean RC, Lue TF. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111–5, quiz116.

    Article  PubMed  Google Scholar 

  103. Smith JF, Shindel AW, Huang Y-C, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl. 2011;13(2):322–5.

    Article  CAS  PubMed  Google Scholar 

  104. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie’s disease: a nationwide survey. J Sex Med. 2008;5(4):954–64.

    Article  PubMed  Google Scholar 

  105. Griffiths MR, Priestley GC. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol. 1992;72(1):15–8.

    CAS  PubMed  Google Scholar 

  106. Weidner W, Hauck EW, Schnitker J, Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530–535; discussion 535–6.

    Google Scholar 

  107. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44(2):291–5.

    Article  CAS  PubMed  Google Scholar 

  108. Akman T, Sanli O, Uluocak N, Akbulut F, Nane I, Demir S, et al. The most commonly altered type of Peyronie’s disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side. Andrologia. 2011;43(1):28–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Vita-Salute San Raffaele, Milan, Italy

    Walter Cazzaniga, Paolo Capogrosso, Francesco Montorsi & Andrea Salonia

  2. Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy

    Walter Cazzaniga, Paolo Capogrosso, Luca Boeri, Francesco Montorsi & Andrea Salonia

  3. Department of Urology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

    Luca Boeri

Authors
  1. Walter Cazzaniga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Capogrosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Boeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Montorsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Salonia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Salonia .

Editor information

Editors and Affiliations

  1. Sheffield Teaching Hospitals NHS Foundation, Sheffield, UK

    Christopher R. Chapple

  2. Department of Urology, University of Virginia, Charlottesville, VA, USA

    William D. Steers

  3. Department of Urologic Surgery, University of California, Davis, Sacramento, CA, USA

    Christopher P. Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cazzaniga, W., Capogrosso, P., Boeri, L., Montorsi, F., Salonia, A. (2020). Pharmacology of Male Sexual Function. In: Chapple, C., Steers, W., Evans, C. (eds) Urologic Principles and Practice. Springer Specialist Surgery Series. Springer, Cham. https://doi.org/10.1007/978-3-030-28599-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28599-9_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28598-2

  • Online ISBN: 978-3-030-28599-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation